TAD disruption and aberrant expression as leukemia metabolic vulnerabilities for novel combination therapy tests in a drug screening platform

TOSCANINI is a European collaborative research project focused on acute and chronic myeloid leukemia. It investigates how changes in the genome’s spatial structure, known as topologically associating domains (TADs), and altered gene activity contribute to disease development. By studying these mechanisms, the project aims to discover new weak points in leukemia cells that can be targeted with tailored drug combinations. RSU is involved in the collection and analysis of patient biological samples, contributing clinical expertise and molecular profiling to support personalized cancer treatment approaches.